Introduction
Many tumors, including those arising in breast, colon, ovary, and prostate, exhibit a "lipogenic" phenotype. This features brisk rates of saturated long-chain FA synthesis driven by enhanced expression of genes coding for the three enzymes required to produce palmitic acid from cytosolic citrate (ATP citrate-lyase, acetyl CoA-carboxylase, and fatty acid synthase (FASN)). Importantly, lipogenic tumor cell growth is slowed in vitro and survival is reduced by FA synthesis inhibitors, whereas nontransformed cells are unaffected (reviewed in (1, 2) ). Moreover, blocking de novo lipogenesis with FASN inhibitors in vivo exerts potent antitumor effects in rodent models of breast (3) and prostate (4) cancer. These observations, coupled with the low rates of fatty acid synthesis in most normal human tissues (5) , have spurred efforts to develop anticancer therapies based on inhibiting lipogenic enzyme activities or silencing the corresponding genes.
Attempts to exploit the metabolic requirements of lipogenic cancers have thus far focused solely on disrupting de novo fatty acid synthesis. Cytotoxicity following inhibition of lipid synthesis, however, may be obviated by the provision of exogenous fatty acids (6) (7) (8) . This observation, and the improved outcome of breast cancer patients ingesting a low fat diet (9) , led us to hypothesize that triglyceride in circulating lipoprotein particles could provide an additional, exogenous source of fatty acids for tumors. This would require triglyceride-rich chylomicrons or very low density lipoproteins (VLDL) as substrate, extracellular lipoprotein lipase (LPL) for hydrolysis, and fatty acid translocase (CD36) for cellular uptake of the free fatty acids (reviewed in (10) ). As LPL is a secreted enzyme that is bound to the luminal surface of capillary endothelial cells, it could 
Materials and Methods
cDNA microarray analysis-Production of the expression dataset has been previously described in detail, as have culture conditions for cell lines ((11), http://cancer.lbl.gov/breastcancer/data.php). RNA from 45 human breast cancer cell lines (ICBP45) grown at subconfluence was harvested, reverse transcribed, and hybridized to Affymetrix U133A gene chips. Resulting Affymetrix image files were normalized (RMA, (12) ). Unsupervised average linkage cluster analysis of log 2 signal intensities was performed using approximately 14,000 probeset IDs of highest variance, using the Cluster Software package, and the resulting dendrogram image produced with Treeview ((13), http://rana.lbl.gov/eisen/?page_id=7). Probeset IDs identifying CD36, LPL and FASN were identified, median centered, normalized and a heat map produced indicating the relative hybridization intensity for each sample.
RT-PCR-RNA was isolated using the RNeasy Mini Kit (Quiagen, Valencia, CA). One μg RNA was reverse transcribed using random hexamer primers with M-MULV reverse transcription (New England Biolabs, Ipswich, MA). PCR was as described (14) . Primers were assessed using a NanoDrop DM-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). RNA was converted to cDNA using Superscript II RT and random hexamer primers, according to the manufacturer's protocol (Invitrogen). Primer sequences for LPL were 5'-TATCCGCGTGATTGCAGAGA-3' (forward) and 5'-GCCTTACTTGGATTTTCTTCATTCA-3' (reverse). Sybr green was used for detection and 18S rRNA was used as an internal control. Primer sequences for 18S were 5'-CGCCGCTAGAGGTGAAATTC-3' (forward) and 5'-TTGGCAAATGCTTTCGCTC-3' (reverse). PCR was in the 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA). The program used included 2 min at 50°C, 1 min at 95°C and 40 cycles of 3 sec at 95°C and 30 sec at 60°C. The average of the Ct-values for each triplicate reaction was expressed relative to the amount of 18S rRNA in the sample.
Tissue culture-LiSa-2 liposarcoma cells were from Martin Wabitsch, University of Ulm, Germany, and we confirmed their identity by the ability to produce lipid droplets that stained with oil red-O upon confluence. All other lines were from ATCC except VCaP, which was from ECACC, and these lines were acquired recently and were of low passage number (< 10). Cells were grown in DMEM:F12 supplemented with 10% fetal calf serum (Atlanta Biologicals, Lawrenceville, GA), 1% penicillin/streptomycin, and 2 mM L-glutamine, in 5% CO 2 at 37 0 C. Cell growth was monitored in an MTT assay (15) .
Lipoprotein deficient fetal calf serum was prepared by the method of Goldstein and coworkers (16) . 10,000 x g for 10 min x 2. Protein content was determined using the BCA assay (Pierce).
Samples were boiled in 2X sample buffer and fractionated through 15% acrylamide. Affinity isolation of LPL-Human milk and conditioned cell culture media were fractionated over heparin sepharose (Sigma) using a procedure modified from Hata and coworkers (17).
LPL activity-We employed the radiochemical assay of Nilsson-Ehle and coworkers (18) or a colorimetric assay based on determination of glycerol production (BioVision, 
Results
We used a cDNA microarray to screen 45 breast cancer-derived cell lines from the dataset of Neve and coworkers (11) S1 ). Expression of LPL mRNA by selected cell lines was verified by RT-PCR (Fig. 1A) , as was expression of CD36 mRNA (Fig. 1B) . LiSa-2 liposarcoma cells, which we previously demonstrated to exhibit the lipogenic phenotype (23), also expressed LPL and CD36, as expected for a tumor cell derived from an adipocytic lineage. All of the cell types expressed substantial FASN mRNA (Fig. 1C) , and in the breast cancer cell lines this did not vary among the gene expression signatures (Supplementary Fig. S1 ).
Quantitative real time RT-PCR of representative lines confirmed that LiSa-2 liposarcoma and triple negative Du4475 breast cancer cells expressed the highest levels of LPL mRNA (Fig. 1D) . In contrast, prostate cancer cells, which are highly lipogenic (24), expressed relatively low levels of LPL mRNA, and ER+ T47D and BT474 breast cancer cells expressed essentially none.
We examined conditioned tissue culture media for LPL enzyme activity, and it paralleled the levels of LPL mRNA ( Fig. 2A) . LPL activity accumulated over time in culture media of LiSa-2 liposarcoma and Du4475 breast cancer cells (Fig. 2B) . In contrast, ER+ T47D, and heparin-releasable LPL activity in a freshly-prepared breast tumor homogenate also reflects on this question, as heparin-releasable activity was readily detectable, arguing against depletion of a cell surface-bound LPL pool in breast tumors (see below).
We performed two experiments to determine whether cancer-associated LPL is bound to tumor cells by noncovalent interactions with cell surface heparan sulfate proteoglycans, using a protocol based on that of Cruz and coworkers (19). First, we homogenized freshly-resected invasive breast cancer tissue shown to contain LPL immunoreactivity (Fig. 2C lower) , and extracted equal aliquots with buffer containing heparin or not. LPL activity in the control sample was 1032 + 8 without heparin, 768 + 4 with heparin treatment (mean + SE, nanomoles glycerol produced/g tumor/h, measured in triplicate; p < 0.0001). This represented a heparin-releasable fraction of 26% of the total tumorassociated LPL activity (represented by the portion of the bar labeled HR, Fig. 2 D left) .
Second, we determined the heparin-releasable fraction of LPL in HeLa cells, and calculated turnover rates for cellular LPL pools (Fig. 2D right) . Residual LPL activity in cell pellets was 13,260 + 1,080 without, and 9,360 + 820 with heparin exposure (units are nanomoles glycerol produced/flask/h, mean + SEM, n= triplicate measurements/group; p < 0.04). We thus estimate that 29% of the HeLa cell-associated pool of LPL is heparin- releasable (indicated by HR on the graph), a fraction similar to that observed in the breast tumor sample. Measurement of LPL activity in culture media indicated that 36,000 + 4,000 units of LPL activity were secreted/24 h. We therefore estimate that the total cellular LPL pool turns over 2.7 times/d, while the heparin-labile pool (3900 units/well) turns over, presumably by secretion, 9.2 times/d.
Our fetal calf serum (FCS) contained 660 mcg triglyceride/ml. LPL secreted by cells is removed when culture media are replaced, so the enzyme content in tissue culture never approaches that observed in tissues. We therefore assessed the functional significance of LPL by adding the enzyme to media containing 10% FCS and measuring cell accumulation. LPL activity under these culture conditions approximated that observed in mouse muscle. LPL enhanced the growth of T47D breast cancer cells, which do not express LPL, and of LiSa-2 liposarcoma cells, which do (Fig. 3A and B) . This effect of LPL was greatly reduced in media containing FCS that was nearly depleted of trigyceride (20 mcg/ml).
LNCaP prostate cancer cell growth was not accelerated by LPL addition. The ability of these cells to use exogenous triglyceride-derived fatty acids to maintain growth was revealed, however, in the presence of Soraphen A, a potent inhibitor of the lipogenic enzyme acetyl CoA-carboxylase (7). The cells were rescued from Soraphen A-induced cytotoxicity by provision of LPL in the presence, but not in the absence, of lipoproteins (Fig. 3C) . Experiments using PC3 prostate cancer cells yielded similar results (Fig. 3D) . 
In complementary studies we assessed the impact of siRNA-mediated knockdown of LPL mRNA on the growth of HeLa cells, which we previously reported to express the LPL gene (25) , and its interaction with inhibition of lipogenesis by Soraphen A. Two different siRNAs each caused > 90% disappearance of LPL mRNA, whereas a nonspecific siRNA was without effect (Fig. 3E) . Soraphen A caused a major inhibition of HeLa cell accumulation, and this effect was prevented by provision of LPL to the cultures (Fig.   3F) . Transfection of LPL siRNA A or B, but not of the nonspecific siRNA, significantly inhibited HeLa cell growth, and the anticancer effects of the two LPL siRNAs were further enhanced by exposure to Soraphen A.
We employed immunohistochemistry to assess the relevance of our findings in cultured cells to human tumors. We assessed the expression of markers of de novo lipogenesis (FASN, THRSP (Spot 14, S14)), lipolysis (LPL), and exogenous FA uptake (CD36), in a panel of 147 breast, 24 liposarcoma, and 10 prostate tumor tissues (examples in Fig. 4) . (Fig. 4C insets) . As expected, extracellular LPL was found on the luminal surfaces of capillaries ( Supplemental Fig. S2C left) . We stained tonsil tissue as a negative control, based on previous work showing undetectable LPL mRNA in lymphoid cells (25) . The lymphoid stroma indeed showed no staining except for scattered isolated monocytes, whereas the highly proliferative basal (stem cell) layer of the mucosal epithelium overlying the tonsil unexpectedly showed a strong signal (Supplemental Fig. S2C right).
The majority of tumors also stained for CD36 (Fig. 4D) . Interestingly, two distinct staining patterns were observed in breast cancer tissue. Of 144 evaluable cores, 42 exhibited diffuse cytoplasmic staining without accentuation at the plasma membrane (Fig. 4D, left upper) , whereas 100 also demonstrated a strong cell surface signal (lower panel). Only 2 breast cancer cases were devoid of staining. Chi square analysis demonstrated a statistically significant difference in the prevalence of the membranous staining pattern between the "triple negative" and ER+ breast cancers (42 vs. 76%, p < 0.02).
Of 25 liposarcoma cases, 21 stained for CD36, almost all in a mixed cytoplasmic plus plasma membrane pattern (Fig. 4D, middle) , including all 9 cases of well-differentiated liposarcoma. Of 9 evaluable prostate cancers, 4 showed focally positive staining in a mixed cytoplasmic and plasma membrane pattern (Fig. 4D, right) , while 5 cases scored negative for CD36. Fig. S3A ). We incubated fibroblasts and DU4475 cells with fluorescently-labeled VLDL particles, and assessed for cellular uptake using confocal microscopy. Abundant uptake was observed in fibroblasts ( Fig. S3B ), but not in DU4475 cells (Fig. S3C) . Occasional fluorescence was detected on the cell surface (Fig. S3D ), but never within the breast cancer cells.
Discussion
Our data demonstrate that cancer cells may use two different mechanisms to acquire fatty acids to fuel proliferation. Breast and liposarcoma tumors are equipped for both lipid synthesis and for LPL-mediated extracellular lipolysis followed by fatty acid uptake via CD36. Prostate cancer cells, which have a very high capacity for de novo lipogenesis (24), express very little LPL. The low LPL expression could be explained in part by the reported loss of heterozygosity at the LPL locus in 47% of prostate tumors, owing to the presence of a nearby tumor suppressor gene (29) . These cells, however, can acquire sufficient exogenous fatty acids to maintain growth in the face of fatty acid synthesis inhibition when they are supplied with LPL and triglyceride-rich lipoprotein particles. 
Various hypotheses have been proposed to explain the dependence of tumors on lipogenesis, but it is clear that the primary metabolic fate of fatty acids in proliferating tumor cells is incorporation into phospholipids destined for membrane biosynthesis (37, 38). As mitochondrial production and export of citrate are the key steps required to maintain de novo lipogenesis in the cytosol, this begs the question of how such mitochondrial metabolism may be maintained under the hypoxic (but not anoxic) conditions that prevail in tumors. Indeed, hypoxia induced factor-1 (HIF-1), a key mediator of the cellular response to hypoxia, reduces the fractional entry of glucosederived carbon into mitochondria by down-regulating pyruvate dehydrogenase, thus driving the increased lactate production that is the most well-recognized aspect of intermediary metabolism in tumors (39). However, net flux of carbon through the glycolytic pathway is substantially elevated in glucose-avid tumor cells, because of increased uptake and trapping. The reduced amount of carbon directed to mitochondria is thus sufficient to provide an estimated 60-85% of the ATP generated (40). Brisk citrate export from mitochondria appears to be favored by incomplete combustion, as a consequence of the "truncated Krebs cycle" in tumor mitochondria (41), which also may serve to reduce oxygen use by reducing carbon flux through steps downstream from citrate in the cycle. Thus, the competing oxygen-sparing and anabolic demands on tumors are met by a balanced set of metabolic alterations, the former favored by HIF-1, and the latter driven by oncogenes (reviewed in (42)). Overall, it appears that the uptake of exogenous fatty acids, for which the current work demonstrates most tumors to be 
